X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Pharma In 2024: The Support & Challenge On Financial Aspect

Content Team by Content Team
4th January 2024
in News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

As per the results of a study done by GlobalData, the top issues when it comes to the pharmaceutical industry in 2024 are going to be inflation, geopolitical conflict, as well as drug pricing pressures. Data outcomes went on to reveal that most respondents from the Pharma gamut considered that drug pricing as well as reimbursement constraints were going to have an adverse effect in 2024.

Inflation as well as geopolitical pressure

The second biggest adverse impact was thought to be arising due to geopolitical conflicts and inflation. As per the Senior Director of Market Research from GlobalData, Urte Jakimaviciute, geopolitical tensions as well as conflicts go on to bring a kind of uncertainty to the economic outlook as certain weakened relationships get often tagged by numerous repercussions that range from decreased cooperation, disruptions of the IPO market, to even economic sanctions.

Drug pricing happened to be considered the most negative upcoming regulatory as well as macroeconomic trend, resulting in dipping growth for the industry, based on the industry outlooks from 2019 to 2022 from GlobalData.

It is well to be noted that, as per Jakimaviciute, price controls, which go on to apply to medicines in most of the major markets, go on to mean that drug prices don’t happen to be typically allowed to increase at the same rate as general inflation. Nonetheless, this may very well go on to limit the revenue growth when it comes to pharma, with production costs increasing. For instance, because suppliers are increasing costs and employees are expecting hikes in pay, drug production costs may go on to rise well above the inflation rates.

Further inferences from the report

But GlobalData summarized that, on the basis of the report, influences that include environmental, social, and corporate governance- ESG factors as well as patent expiration of biologics are forecasted to positively affect the pharmaceutical sector in the years to come, with the latter enabling to streamline operations and at the same time generate growth.

The pharmaceutical sector will require to innovate as well as increase resilience so as to accelerate market expansion, the company went on to highlight. The report went on to recommend that, so as to get a competitive edge in the market, emphasizing modernizing R&D models or even implementing emerging technologies could go on to support this endeavor.

Finally, as per the research, two other upcoming industry trends within the biopharmaceutical sector are immuno-oncology drug development as well as real-world evidence- RWE.

Previous Post

Drugmakers Look To Raise US Prices On 500 Drugs In Jan 2024

Next Post

Synergising SaaS & Cloud Comm With AI For Better Pharma

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Next Post
Synergising SaaS & Cloud Comm With AI For Better Pharma

Synergising SaaS & Cloud Comm With AI For Better Pharma

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In